699 related articles for article (PubMed ID: 30885244)
21. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
22. CD1d is a novel cell-surface marker for human monocytic myeloid-derived suppressor cells with T cell suppression activity in peripheral blood after allogeneic hematopoietic stem cell transplantation.
An B; Lim JY; Jeong S; Shin DM; Choi EY; Min CK; Hong SH
Biochem Biophys Res Commun; 2018 Jan; 495(1):519-525. PubMed ID: 29108995
[TBL] [Abstract][Full Text] [Related]
23. The mechanistic study behind suppression of GVHD while retaining GVL activities by myeloid-derived suppressor cells.
Zhang J; Chen HM; Ma G; Zhou Z; Raulet D; Rivera AL; Chen SH; Pan PY
Leukemia; 2019 Aug; 33(8):2078-2089. PubMed ID: 30737483
[TBL] [Abstract][Full Text] [Related]
24. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
[TBL] [Abstract][Full Text] [Related]
25. Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease.
Gómez-Almaguer D; Gómez-Peña Á; Jaime-Pérez JC; Gómez-Guijosa MÁ; Cantú-Rodríguez O; Gutiérrez-Aguirre H; Martínez-Cabriales SA; García-Rodríguez F; Olguín-Ramírez LA; Salazar-Riojas R; Méndez-Ramírez N
J Clin Apher; 2013 Oct; 28(5):349-55. PubMed ID: 23682006
[TBL] [Abstract][Full Text] [Related]
26. Effect of upregulated TLR2 expression from G-CSF-mobilized donor grafts on acute graft-versus-host disease.
Lee WS; Kim JY; Won HJ; Lee SM; Suh YS; Joo YD; Lee JY; Jang WH; Kang SW; Kang MS; Park SG; Choi IW; Choi I; Seo SK
Int Immunopharmacol; 2015 Dec; 29(2):488-493. PubMed ID: 26462591
[TBL] [Abstract][Full Text] [Related]
27. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
Pan L; Teshima T; Hill GR; Bungard D; Brinson YS; Reddy VS; Cooke KR; Ferrara JL
Blood; 1999 Jun; 93(12):4071-8. PubMed ID: 10361103
[TBL] [Abstract][Full Text] [Related]
28. Differences in kinetics of donor lymphoid cells in response to G-CSF administration may affect the incidence and severity of acute GvHD in respective HLA-identical sibling recipients.
Trzonkowski P; Zaucha JM; Mysliwska J; Balon J; Szmit E; Halaburda K; Bieniaszewska M; Mlotkowska M; Hellmann A; Mysliwski A
Med Oncol; 2004; 21(1):81-94. PubMed ID: 15034218
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease.
Pan L; Delmonte J; Jalonen CK; Ferrara JL
Blood; 1995 Dec; 86(12):4422-9. PubMed ID: 8541530
[TBL] [Abstract][Full Text] [Related]
30. Day 4 collection of granulocyte colony-stimulating factor-mobilized HLA-matched sibling donor peripheral blood allografts demonstrates no long-term increase in chronic graft-versus-host disease or relapse rates.
Booth G; Yu Y; Harlan RP; Jacoby CE; Tomic KM; Slater SE; Allen BE; Berklich EM; Knight RJ; Dela Cruz J; Fu R; Gandhi A; Cook RJ; Meyers G; Maziarz RT; Newell LF
Cytotherapy; 2023 Apr; 25(4):423-431. PubMed ID: 36690537
[TBL] [Abstract][Full Text] [Related]
31. Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model.
Adhikary SR; Cuthbertson P; Nicholson L; Bird KM; Sligar C; Hu M; O'Connell PJ; Sluyter R; Alexander SI; Watson D
Immunology; 2021 Oct; 164(2):332-347. PubMed ID: 34021907
[TBL] [Abstract][Full Text] [Related]
32. Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13.
Highfill SL; Rodriguez PC; Zhou Q; Goetz CA; Koehn BH; Veenstra R; Taylor PA; Panoskaltsis-Mortari A; Serody JS; Munn DH; Tolar J; Ochoa AC; Blazar BR
Blood; 2010 Dec; 116(25):5738-47. PubMed ID: 20807889
[TBL] [Abstract][Full Text] [Related]
33. Donor-Derived Myeloid Heme Oxygenase-1 Controls the Development of Graft-Versus-Host Disease.
Spilleboudt C; De Wilde V; Lewalle P; Cabanne L; Leclerc M; Beckerich F; Bories D; Cardoso S; Soares MP; Vokaer B; Hougardy JM; Flamand V; Racapé J; Abramowicz M; Maury S; Le Moine A
Front Immunol; 2020; 11():579151. PubMed ID: 33537027
[TBL] [Abstract][Full Text] [Related]
34. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
35. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
Huang X; Liu D
Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
[TBL] [Abstract][Full Text] [Related]
36. [Effect of granulocyte colony stimulating factor on myeloid-derived suppressor cells in the bone marrow and peripheral blood: a preliminary study].
Ling YW; Liu QF; Liu C; Wu XL; Chen YK; Fan ZP; Xuan L; Zhang Y; Jiang QL; Zhao J; Sun J
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Jun; 31(7):1190-2. PubMed ID: 21764692
[TBL] [Abstract][Full Text] [Related]
37. G-CSF-Mobilized Blood and Bone Marrow Grafts as the Source of Stem Cells for HLA-Identical Sibling Transplantation in Patients with Thalassemia Major.
Li Q; Luo J; Zhang Z; Liu L; Luo L; Yang G; Liu R; Shi L; Huang R; Wu M; Lai Y
Biol Blood Marrow Transplant; 2019 Oct; 25(10):2040-2044. PubMed ID: 31207293
[TBL] [Abstract][Full Text] [Related]
38. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
39. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
40. Role of CD4+CD25+highFoxp3+CD62L+ regulatory T cells and invariant NKT cells in human allogeneic hematopoietic stem cell transplantation.
Vela-Ojeda J; Montiel-Cervantes L; Granados-Lara P; Reyes-Maldonado E; García-Latorre E; Garcia-Chavez J; Majluf-Cruz A; Mayani H; Borbolla-Escoboza JR; Esparza MG
Stem Cells Dev; 2010 Mar; 19(3):333-40. PubMed ID: 19919293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
